

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

October 23, 2019

Alexander Arrow Chief Financial Officer Protagenic Therapeutics, Inc.\new 149 Fifth Avenue New York, New York 10010

> Re: Protagenic Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2018 Filed March 29, 2019 File No. 000-51353

Dear Mr. Arrow:

We have limited our review of your filing to the financial statements and related disclosures and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

#### Form 10-K filed March 3, 2019

### Signatures, page 60

1. The annual report should also be signed by Alexander K Arrow in his capacity as the Chief Accounting Officer or Controller. Please revise. Refer to General Instruction D2(a) to Form 10-K.

### Note 6 Stockholders' Equity (Deficit), page F-14

2. Please tell us your consideration of disclosing the weighted-average grant-date fair value of equity options granted during the years presented. Refer to ASC 718-10-50-2d.1.

## Note 5 Derivative Liabilities, page F14

3. We note your disclosure that the cashless exercise feature requires you to classify warrants as a derivative liability. Please explain to us in detail how this cashless exercise feature results in liability classification under existing accounting literature.

Alexander Arrow Protagenic Therapeutics, Inc.\new October 23, 2019 Page 2

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

You may contact Tony Watson at (202) 551-3318 or Bill Thompson at (202) 551-3344 with any questions.

Sincerely,

Division of Corporation Finance Office of Trade & Services